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PEMBANGUNAN STRATEGI MENGIMMOBILISASI ANTIBODI DENGAN 
MENGGUNAKAN REKOMBINAN Fc RESEPTOR NEONATAL MANUSIA 
 
ABSTRAK 
Antibodi immobilisasi merupakan asas utama kepada asai yang melibatkan 
antibodi dalam teknologi biopengesanan. Teknologi tersebut biasa digunakan untuk 
mengesan and mengukur kebanyakan jenis molekul biologi seperti antigen, 
biomarker, allergen and bahan-bahan perubatan. Maka, interaksi yang spesifik antara 
antibodi dengan ligan amat diperlukan untuk menjamin penghasilan semula 
keputusan dan juga sensitiviti. Komplesiti mengimmobilisasi antibodi adalah faktor 
utama yang mempengaruhi keputusan sesuatu asai kerana molekul pengecaman, 
seperti antibodi, mungkin mengalami perubahan dan kehancuran struktur semasa ia 
dilekatkan pada permukaan pepejal. Untuk memenangi situasi tersebut, cara baharu 
mengimmobilisasi antibodi amat diperlukan pada masa kini. Kajian ini berusaha 
untuk meneroka protein pengikat antibodi yang baharu, iaitu Fc reseptor neonatal 
manusia. Protein ini mempunyai afiniti yang tinggi terhadap bahagian Fc pada 
antibodi sama ada dalam keadaan in vivo ataupun in vitro. Ia adalah suatu 
heterodimer yang dibentuk daripada dua komponen: p51 rantai berat-α (rantai-α) dan 
β2-microglobulin rantai ringan. Kajian telah melaporkan bahawa semua molekul 
yang terlibat dalam interaksi dengan antibodi hanya terletak pada rantai-α sahaja. 
Dengan itu, kajian ini akan menggunakan rantai-α sahaja untuk mengimmobilisasi 
antibodi. cDNA yang mengekodkan rantai-α (hFcRn-α) telah diklonkan dalam vektor 
ekspresi bacteria. Banyak usaha telah dilakukan untuk menghasilkan Fc reseptor 
neonatal manusia dalam bentuk larut di dalam bakteria. Cara tersebut berbeza dengan 
kaedah biasa yang menghasilkan Fc reseptor neonatal manusia di dalam sel mamalia. 
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Pertambahan betaine dengan kenaikan suhu yang singkat semasa pertumbuhan 
bakteria telah berjaya meningkatkan pelarutan protein rekombinan yang dihasilkan. 
Beberapa asai fungsian termasuk ELISA, analisis pH-bergantungan, dan dot blot 
imunoasai telah dijalankan untuk mengenal pasti aktiviti asli protein rekombinan 
tersebut. Keputusan menunjukkan bahawa hFcRn-α yang dihasilkan dengan cara 
tersebut adalah aktif dan berfungsi. Selain itu, kaedah tersebut tidak memerlukan 
protokol melipat-semula protein untuk memulihkan aktivitinya. Kajian ini 
melaporkan suatu kaedah yang senang dan efektif untuk menghasilkan Fc reseptor 
neonatal manusia. Protein rekombinan tersebut telah digunakan untuk 
mengimmobilisasi IgG arnab terhadap antigen permukaan virus hepatitis B. 
Keputusan ELISA menunjukkan bahawa immobilisasi antibodi tersebut adalah 
bertindak langsung dengan kepekatan hFcRn-α yand terdapat di dalam plat ELISA. 
Kajian juga dilanjutkan untuk membangunkan asai ELISA sandwich bagi 
pengesanan antigen permukaan virus hepatitis B degan menggunakan hFcRn-α 
sebagai protein pengikat antibodi.  Keputusan yang dihasilkan telah dibandingkan 
dengan sistem pengesanan yang menggunakan pelekatan antibodi fizikal. Perbezaan 
kedua-dua system tersebut telah dikaji dengan ujian-t dua sampel. Keputusan 
mengimbaskan bahawa antibodi immobilisasi yang melibatkan hFcRn-α dapat 
menghasilkan isyarat pengesanan yang lebih tinggi berbanding dengan pelekatan 
antibodi fizikal, terutamanya pada kepekatan antigen permukaan virus hepatitis B 
yang bernilai 1 µg per isi. Secara keseluruhannya, kajian ini melaporkan calon 
baharu protein pengikat antibodi yang berpotensi mengimmobilisasikan antibodi 
dalam orientasi yang betul tanpa sebarangan perubahan struktur antibodi.  
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DEVELOPMENT OF ANTIBODY IMMOBILISATION STRATEGY USING 
RECOMBINANT HUMAN NEONATAL Fc RECEPTOR 
 
ABSTRACT 
Antibody immobilisation is the cornerstone of antibody-based assay in 
biosensing technology which is predominantly used to detect and measure a wide 
variety of biological analytes, ranging from antigens, biomarkers, allergens and drug 
substances. As such, specific interactions between antibody and ligands are therefore 
needed to guarantee highest reproducibility and sensitivity possible. The complexity 
of pinning antibodies forms the key factor in interfering the outcome of an assay as 
the recognition molecule, i.e. the antibody itself, may have undergone structural 
changes and distortion when it is attached to the solid phase. In view of this, there is 
a need to identify new methods and novel strategy in immobilising antibody to 
secure the biosensing system. The present study sought to discover a new candidate 
of antibody binding protein, the human neonatal Fc receptor. This protein has shown 
its high affinity specifically towards Fc region of antibody either in vivo or in vitro. It 
is a heterodimer constructed of two subunits: p51 α-heavy chain (α-chain) and the 
β2-microglobulin light chain. Literatures have revealed its binding sites towards 
antibody and all of the residues involved are solely found in the α-chain. As a result, 
the α-chain alone was used for antibody immobilisation in the present study. The 
cDNA encoding for the α-chain of human neonatal Fc receptor (hFcRn-α) was 
cloned into a bacterial expression vector. Attempts had been made to express the 
soluble form of human neonatal Fc receptor in bacteria instead of the conventional 
approach which uses mammalian cells. The addition of betaine with a brief heat 
shock step during cultivation had successfully enhanced the solubility of 
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recombinant protein expressed. Several functional assays including ELISA, pH-
dependency analysis and dot blot immunoassays were conducted to validate the 
native activity of the recombinant protein. The findings indicated that the hFcRn-α 
produced using this approach remained active, functional and more importantly, 
protein refolding steps were not required to revive its activity. This study presented a 
simple yet effective approach to express human neonatal Fc receptor. The 
recombinant protein was employed to immobilise rabbit IgG against hepatitis B virus 
surface antigen. The ELISA results showed that immobilisation of the particular 
antibody were directly proportional to the concentration of hFcRn-α coated in the 
ELISA plate. Study was extended further to develop a sandwich ELISA to detect 
hepatitis B virus surface antigen using hFcRn-α as antibody binding protein. The 
results were compared to the detection system developed using physical adsorption 
of the antibody. The differences in the detection signals generated by these two 
strategies were validated using independent t-test. The finding highlighted that 
hFcRn-α directed immobilisation yielded higher signals in antigen detection 
compared to physical adsorption method, especially at the concentration of hepatitis 
B virus surface antigen of 1 µg per well. Ultimately, the present study reported a new 
candidate of antibody binding protein which is capable of immobilising antibody in a 
proper orientation without additional antibody modification steps. 
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CHAPTER 1 
INTRODUCTION 
1.1  Antibody structure and classes 
Antibodies, also termed as immunoglobulins, are glycoprotein molecules that 
bind to target antigens with high specificity. In human, this unique recognition 
molecule can be classified into five classes based on its structure and biochemical 
properties: IgG, IgA, IgM, IgD and IgE (Woof and Burton, 2004). Table 1.1 
demonstrates the comparison of the different classes of antibodies in human. 
All classes of antibodies have its general structure constructed by four 
polypeptide chain units: two light (L) chains and two heavy (H) chains. Disulfide 
bonds are the key chemical bonds that cross-link the L-chains and H-chains together 
to form a functional structure. Both H-chains and L-chains consist of amino-terminal 
variable (V) regions that involve in antigen recognition and carboxy-terminal 
constant (C) regions. The C regions of H-chains participate in effector function. All 
antibodies of same class are similar in the amino acid sequences and numbers in their 
C regions. However, the V regions are different between antibodies of different types 
(Wang et al., 2007). More importantly, intrachain disulfide bonds are found in both 
L-chains and H-chains which create polypeptide loops, also known as domains, in 
the antibody. These domains are named as VH, VL, CH1, CH2 and CH3. The VH and 
VL domains play important tole in forming the antigen-binding site of antibody 
(Figure 1.1). 
Among the five classes of antibodies, IgG is the most abundant and widely 
used for therapeutic pusrposes. This particular class of antibody has also been 
thoroughly explored in the antibody immobilisation on solid phase for biosensor 
development.  
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Table 1.1 Properties and classes of human antibodies. 
 
 IgG IgA IgM IgD IgE 
Physical 
properties 
     
Molecular weight, 
kDa 
150 170-420 900 180 190 
Molecular weight 
of H-chain, kDa 
50-55 62 65 70 75 
Main molecular 
form 
Monomer Monomer 
and dimer 
Pentamer Monomer Monomer 
Physiological 
properties 
     
Normal adult 
serum (mg/ml) 
8-16 1.4-4.0 0.4-2.0 0.03 < 0.03 
Half-life (days) 23 6 5 3 < 3 
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Figure 1.1 Schematic depiction of IgG. All classes of antibodies share similar 
general structure which constituted of two heavy (H) chains and two light (L) chains. 
The constant (C) regions and variable (V) regions are shown in the figure (Trilling et 
al., 2013).  
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1.2  Concept of antibody immobilisation 
Antibody immobilisation is a technique to circumscribe antibodies to a solid 
phase with retention of its native affinity to target antigens. This technology is of 
considerable interest in the application of antibody-based assay systems, especially 
diagnostic platforms. Most of the diagnostic assays involve manipulation of 
antibodies in the detection and identification of biological molecules in the biological 
samples, such as the detection of cancer biomarkers and pathogens, measurement of 
hormones, quantifying drugs in urine and also other miscellaneous fields of interest 
(Skottrup et al., 2008; Ambrosi et al., 2010; Phan et al., 2012; Pla-Roca et al., 2012; 
Bertholf et al., 2015; Shi et al., 2015; Pankhurst and McLennan, 2016). Those 
molecular identification and quantification are critical in forensic investigations, 
early illness detections and healthcare services involving monitoring of disease 
progression and treatment options. Consequently, the affinity and sensitivity of the 
assay system becomes an important key factor as it may shift the result of a diagnosis 
or a professional decision into different direction when inaccuracy of detection 
ensued. More importantly, this scenario is subjected to the complexity of the 
antibody immobilisation strategy as different methods of pinning antibodies will 
significantly affect the affinity and sensitivity of an assay (Vashist et al., 2011; 
Trilling et al., 2013). 
An antibody-based assay system is constructed by two main components: the 
antibody that captures target antigens and the solid phase where the antibodies are 
attached. The antigen-binding sites are located at the Fab (fragment antigen-binding) 
regions of the antibody while the Fc (fragment crystallisable) region is the 
attachment site to the solid surface. There are various types of solid surfaces used, 
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predominantly glass, gold, polystyrene, nitrocellulose membrane and silicone (Hahn 
et al., 2008). Figure 1.2 illustrates the basic construction of antibody-based assay. 
 
1.3  Critical consideration in antibody immobilisation 
Several crucial factors must be considered during antibody attachment as the 
immobilisation methods of choice will significantly interfere with the result of an 
assay. Predominantly, three factors have been identified: the orientation of 
immobilised antibodies, the stability of immobilised antibodies and the density of 
immobilised antibodies. 
 
1.3.1 Orientation of immobilised antibodies 
In the assay detection, the Fab regions of an antibody contain specific binding 
sites for its antigens. It is ideal that all of the Fab regions of antibodies are oriented 
upward, away from the solid surface, to allow maximal capture of antigens. 
Nevertheless, the interaction between antigens and antibodies will reduce if the 
antibodies exist in random orientation on the solid phase (Figure 1.3). This scenario 
happened due to the steric hindrance generated by the solid surface itself or the 
adjacent antibodies (Kausaite-Minkstimiene et al., 2010; Song et al., 2012). Part of 
the Fab regions may be blocked and impeded from binding with antigens in the 
random antibody orientation. Study done by Bonroy et al. (2006) showed that the 
oriented immobilisation produced 2-fold higher in the antigen binding signals 
compared to the antibodies in random orientation. In addition, a study reported by 
Tsai and Pai (2009) highlighted that the oriented immobilisation of antibody 
fragments had demonstrated 50% increase in the antigen binding efficiency in the  
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Figure 1.2 The principle of an antibody-based assay. The assay system is 
constructed of two main components: the antibody and the solid phase where the 
antibody is pinned. 
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Figure 1.3 The orientation of antibodies on solid surface. (A) Random 
immobilisation of antibodies generates random orientation and thus it limits the 
antigen detection in the assay. (B) Oriented antibody immobilisation allows all Fab 
regions of antibodies facing away from the solid surface. This immobilisation 
approach maximises antigen-antibody interaction. 
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detection of Staphylococcus enterotoxin B compared to the random antibody 
immobilisation method.    
 
1.3.2 Stability of immobilised antibodies 
The amounts of active recognition molecules present in a biosensor always 
draw major attention when designing a diagnostic assay. In some situations, 
antibodies can be covalently immobilised via self-assembled monolayers of 
alkanethiol or via specific linkage of biotin-streptavidin (Subramanian et al., 2006; 
Cho et al., 2007). Some literatures proposed applications of pepsin-digested antibody 
fragments for assay development (Vallina-Garcia et al., 2007; Nassef et al., 2009). 
However, those procedures are cumbersome and these immobilisation methods may 
distort the structure of antibodies, leading to the conformational changes in the 
antigen-binding sites (Figure 1.4). As a result, the target antigens are unable to 
interact with antibodies, even though oriented antibody immobilisation is applied 
(Zhu and Snyder, 2003). This scenario significantly reduces the sensitivity of the 
assay and false negative results may arise. It is crucial to maintain the intact structure 
of antibodies and thus, modification of antibody during immobilisation step should 
be avoided. Study conducted by Vashist (2012) revealed that the modified 
antibodies, such as biotin conjugation, tetramethylrhodamine isothiocyanate 
(TRITC)-labelled and Atto 550 fluorescent labelled, has adversely affected the 
specific binding affinity of antibodies to its analytes in the surface plasmon 
resonance (SPR) analysis. His finding reported that unmodified antibodies showed 
higher sensitivity compared to the modified antibodies.   
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Figure 1.4 Stability of antibodies may be affected by the selected immobilisation 
strategy. (A) The whole structure of antibodies remain intact after attachment to the 
solid surface. Antibodies retain its native affinity towards analytes. (B) The antigen-
binding sites of antibodies had been changed owing to the immobilisation method 
and thus, leading to the reduction in the affinity of antibodies.  
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1.3.3 Density of immobilised antibodies 
Attempts had been made to increase the numbers of immobilised antibodies 
per unit area on the solid surface. This approach is marked as production of high 
density biosensor (Ruan et al., 2008; Gaster et al., 2011). Contrarily, in low density, 
there are fewer numbers of immobilised antibodies per unit area (Figure 1.5). The 
demand for high density biosensors places increasing pleasure on the current 
analytical technology, predominantly disease detection. At the early stage of 
infection or tumor proliferation, there is low abundance of biomarkers present in the 
clinical samples (Harris et al., 2007; Liu and Li, 2012; Duffy, 2013). A high density 
biosensor with enhanced limit of detection is expected to be able to identify and 
quantify the target analytes, even though the quantity is minute. Nevertheless, a 
biosensor with low antibody density may generate false negative result, due to the 
probability for the antibody to interact with antigen is too low and thus it is 
insufficient to be translated into a quantifiable signal. 
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Figure 1.5 Density of immobilised antibodies will interfere the sensitivity of an 
assay. (A) At high density, there are large numbers of antibodies attached to the solid 
surface per unit area. (B) At low density, only a few antibodies are attached to the 
solid surface per unit area. 
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1.4  Strategies of antibody immobilisation 
Advance methods of antibody immobilisation had been reported up to date, 
all these approaches can be classified into three categories: physical adsorption, 
covalent coupling and modification, and antibody binding proteins. 
 
1.4.1 Physical adsorption 
Antibody can be directly immobilised to a solid phase through non-specific 
interactions, such as hydrophobic and hydrophilic interactions. This method is 
marked as physical adsorption (Figure 1.6). This approach does not involve covalent 
bonding and thus omits the sophisticated pre-treatment procedures of solid phase 
(Butler et al., 1992; Qian et al., 2000; Pavlickova et al., 2004). In view of this, 
physical adsorption of antibody can be carried out easily in laboratories with basic 
equipment and materials. The minimal antibody-surface handling procedure and cost 
efficiency have added major advantages for this strategy. The solid phase used for 
antibody immobilisation can be a plastic surface or nitrocellulose membrane. 
Nevertheless, the drawbacks created by the physical adsorption method have 
overshadowed its advantages. Due to the formation of weak interactions between 
antibodies and the solid surface, the adsorbed antibodies may slowly leach from the 
surface itself. This limits the possibility of long-term storage for future detection 
purposes. Furthermore, the density of antibody generated using this method is not 
always very high. Besides, it is noteworthy that only 20 – 30% of antibodies 
immobilised using this strategy appear in the proper oriented manner (Angenendt et 
al., 2002; Taussig and Landegren, 2003). This makes the detection difficult when the 
analytes are in microscale or nanoscale concentration. Physical adsorption of 
antibody will promote conformational change in the structure due to direct contact  
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Figure 1.6 Antibody immobilisation through physical adsorption. This strategy 
relies on the non-specific interaction of antibody to the solid phase. As a result, the 
antibodies immobilised will exhibit in random orientation manner. 
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with the surface and thus leading to antibody denaturation (Butler et al., 1993). All 
these situations will lower the limit of detection by the assay system. 
Recent studies have suggested the employment of porous silicon as solid 
phase for physical adsorption of antibody (Jane et al., 2009). One benefit of using 
porous silicon attributed to its large surface area to volume ratio. This allows loading 
of large amounts of biological molecules in a minuscule volume. Naddaf and Al-
Mariri (2011) presented a procedure to immobilise antibody against human 
interleukin-6 in porous silicon. The efficiency of porous silicon in pinning antibody 
was studied with several spectroscopy techniques includes Fourier transformation 
infrared (FTIR) absorption spectroscopy, X-ray photoelectron spectroscopy (XPS) 
and photoluminescence (PL) spectroscopy  Although the results implied the potential 
use of porous silicon in antibody immobilisation through physical adsorption, 
however, there were no functional assays conducted to validate the native affinity of 
the antibody. Furthermore, in their study, the antibody coating period required was 
48 hours at 4°C. It is longer than the conventional physical adsorption of antibody 
performed nowadays. For example, in enzyme-linked immunosorbent assay (ELISA) 
with a conventional polystyrene surface, only an overnight incubation 
(approximately 16 hours) at 4°C is needed. On the other hand, Yan et al. (2011) 
reported a modified method of physical adsorption of antibody on porous silicon 
which required shorter antibody coating time, approximately 30 – 60 minutes. 
Angiotensin I antibody was loaded onto porous silicon surface followed by detection 
of angiotensin I in the samples. Matrix-assisted Laser Desorption/Ionisation Mass 
spectrometry (MALDI MS) was used to analyse the result of detection. Their 
findings pinpointed the advantages of physical adsorption of antibody onto porous 
silicon as the results yielded lower background signals with addition of high antibody 
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density. Nevertheless, the use of porous silicon for physical adsorption of antibody 
necessitates additional treatment step to stabilise the matrix used. This makes the 
approach become cumbersome and also lacking of cost efficiency. Studies should 
concentrate on improving the outcome of antibody immobilisation with minimal 
sophisticated result interpretation. 
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1.4.2 Covalent coupling and modification 
Antibody immobilisation via covalent coupling becomes a preference in the 
past decades. This approach relies on chemical treatment on the solid phase in order 
to be able to form covalent bonding with the specific functional groups in antibody. 
One common example is via amino groups in antibody. The solid surface is 
chemically treated to generate free carboxyl groups. Soluble activator, such as N-
hydroxysuccinimide/1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (NHS/EDC), 
is introduced to initiate cross-linking between the free amino groups of antibody and 
the carboxyl groups on solid surface (Figure 1.7A). A stable covalent bonding is 
formed and allowed antibody to be immobilised on the solid phase (Danczyk et al., 
2003; Kumada, 2014). This approach is known as amine coupling which has 
commonly used in SPR analysis. Nevertheless, due to the presence of multiple free 
amino groups in an antibody, this method will create random antibody orientation on 
the solid phase and, potentially, a reduction in assay sensitivity.  
The trend of covalent coupling of antibody has evolved to the use of 
bifunctional cross-linkers to attach antibody to solid surface (Wang and Jin, 2004; 
Cao et al., 2007; Raj et al., 2009). Bifunctional cross-linker acts as a bridge to 
connect two adjacent molecules which possess either the same functional groups 
(homobifunctional cross-linkers) or different functional groups (heterobifunctional 
cross-linkers). The adoption of bifunctional cross-linker in antibody immobilisation 
relies on its unique feature of long spacer arm. This characteristic minimises the 
steric hindrance generated by the solid phase itself and makes the antigen-binding 
sites more accessible to the target antigens. One commonly used homobifunctional 
cross-linker is glutaraldehyde, which forms cross-linking between amino groups of 
two adjacent molecules (Batalla et al., 2008; Huy et al., 2011). In a research 
 17 
 
conducted by Gunda et al. (2014), the silicon surface was priorly treated with (3-
aminopropyl)triethoxysilane (APTES) to generate amino groups on the surface 
(Figure 1.7B). It was followed by a reaction with glutaraldehyde reagents to produce 
glutaraldehyde-activated surface. Antibodies were then immobilised through its free 
amino groups in the structure. A uniform and homogenous surface with high density 
of antibody was observed through surface analytical techniques such as atomic force 
microscopy. On the other hand, antibody immobilisation through heterobifunctional 
cross-linker, such as N-γ-maleimidobutyryl-oxysuccinimide ester (GMBS), had been 
demonstrated by Corso et al. (2008). In their study, zinc oxide was selected as the 
solid phase for attachment of antibody. 3-mercaptopropyltrimethoxysilane (MTS) 
was treated on the zinc oxide surface to generate free sulfhydryl groups. GMBS, a 
heterobifunctional cross-linker which targets on sulfhydryl group and amino group, 
was reacted to the modified surface. Antibody with its free amino groups was then 
interacted with GMBS to immobilise on the solid surface (Figure 1.7C). Functional 
assay was conducted and the result reflected that the antibody maintained its native 
activity. 
On the other hand, oriented antibody immobilisation through covalent 
coupling can be achieved by targeting specific molecules or functional groups which 
present at the Fc region of antibody. Several studies had shown that the carbohydrate 
side chains present at CH2 domains of antibody are potential candidates for oriented 
covalent coupling (Vijayendran and Leckband, 2001; Franco et al., 2006). Peluso et 
al. (2003) demonstrated an approach of antibody immobilisation through biotinylated 
carbohydrate side chains of Fc fragment (Figure 1.8). In their study, the carbohydrate 
side chains presented at CH2 domains were oxidised to produce aldehyde groups.  
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Figure 1.7 Covalent coupling of antibody to solid phase. Several approaches are 
demonstrated either through (A) amino groups; (B) homobifunctional cross-linker; 
(C) heterobifunctional cross-linker. 
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Figure 1.8 Antibody immobilisation through the specific interaction between 
biotin-streptavidin.  
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This made the structure susceptible for biotinylation by biotin reagent. The site-
specific biotinylated antibody was then immobilised onto a streptavidin coated 
surface. This method utilised the specific interaction between biotin and streptavidin 
to form a stable covalent coupling. The finding reported an increase in approximate 
of 33% in the antigen binding activity compared to random biotinylated antibody.  
Alves et al. (2013) had described a new strategy of oriented covalent 
coupling targeted on the nucleotide binding site of antibody. Nucleotide binding site 
is a highly conserved region found in the Fab of antibody in all isotypes from various 
species (Rajagopalan et al., 1996). This binding pocket is constituted of four amino 
acid residues: two residues of tyrosine in the variable region of light chain; one 
tyrosine and one tryptophan in the variable region of heavy chain. These amino acids 
carry aromatic side chain in their structure. Importantly, exposing the aromatic side 
chains to UV light (254 nm) triggers formation of new covalent bond with another 
aromatic ring in close proximity. This feature was utilised in the study of Alves and 
colleagues for photocross-linking of the nucleotide binding site to an aromatic ligand 
namely indole-3-butyric acid (IBA). IBA was prior conjugated with biotin reagent to 
generate IBA-EG11-biotin. Antibodies were incubated with IBA- EG11-biotin 
followed by UV irradiation (Figure 1.9). This step allowed covalent linking between 
the nucleotide binding site of Fab and the aromatic ring in the IBA. The IBA-EG11-
biotin functionalised antibodies were then immobilised onto a streptavidin coated 
surface. The sensing system produced was validated through detection of prostate 
specific antigen. The result showed that antibody immobilisation through this 
approach generated higher sensitivity for more than 3- fold in the detection of 
prostate specific antigen compared to the amine coupling immobilisation.  
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Figure 1.9 Covalent coupling of antibody by targeting the nucleotide binding 
sites at Fab regions.  
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Modification of antibody structure is a common approach in the covalent 
coupling of antibody. The disulfide bonds between two heavy chains of antibody can 
be split using reducing agent such as 2-mercaptoethylamine into two half-
immunoglobulin G (half-IgG) fragments. This strategy enables antibody attachment 
to the gold surface through the free thiol (-SH) groups yielded (Figure 1.10A). 
Studies claimed that this method of antibody modification did not interfere with the 
antigen-binging sites of antibody yet producing oriented half-IgG on the solid phase 
(Karyakin et al., 2000; Wang et al., 2005). Billah et al. (2010) presented a method to 
attached anti-myoglobin half-IgG fragments employing the cross-linking function of 
heterobifunctional cross-linker, succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-
carboxyl (sulfo-SMCC). This cross-linker was used to couple the amino-terminated 
gold surface and the free thiol groups in half-immunoglobulin fragments. Myoglobin 
detection in serum was carried out using the sensing system developed. The result 
reported an enhancement in the limit of detection, with range of concentration from 
10
-13
 M to 10
-6
 M, compared to the immobilisation of whole anti-myoglobin antibody 
through biotin/avidin strategy which showed detection range of concentration from 
10
-12
 M to 10
-6
 M (Billah et al., 2007). 
Some researches had favoured the use of smaller antibody fragments for 
development of immunoassays. A popular method of preparing antibody fragment 
involved pepsin digestion of antibody to form F(ab‘)2 fragment and numerous 
smaller peptides of Fc. The F(ab‘)2 fragment was subjected to reduction process by 
2-mercaptoethylamine to produce Fab‘ fragments (Brogan et al., 2003). This 
approach produced free thiol group in opposition to the antigen-binding site of Fab‘ 
fragments. The free thiol group formed in Fab‘ fragments facilitated immobilisation 
on gold surface (Figure 1.10B). Functional assays, such as detection of C-reactive  
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Figure 1.10 Antibody immobilisation through production of antibody fragments. 
  
